ReviewExpert opinion on drug metabolism & toxicology2025
Development and hepatotoxicity of rifamycin derivatives.
Review in Expert opinion on drug metabolism & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionRifamycins are a class of antibiotics crucial for the treatment of tuberculosis (TB). Although the development of rifamycin derivatives has revolutionized TB therapy, they are associated with hepatotoxicity, which limits their clinical use. AREAS COVERED: This review summarizes the development, clinical applications, and hepatotoxicity of rifamycin derivatives. We highlight the mechanisms of rifamycin drug-induced liver injury (DILI) and discuss strategies to improve the safety profiles of rifamycin derivatives. Relevant literature was reviewed by searching PubMed and SciFinder for articles published up to January 2025. EXPERT OPINION: The hepatotoxicity of rifamycin derivatives remains a challenge in clinical practice. Further research is needed to clarify the detailed mechanisms of rifamycin-induced liver injury. Mechanism-based strategies are also expected to prevent the toxicity of rifamycin derivatives.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.